Celsion recently reported that a presentation given by Ronnie T.P. Poon on the Celsion's cancer treatment product ThermoDox had been given at the 2012 Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe, being held September 15-19 in Lisbon, Portugal. Celsion stated that the presentation involved the need to consolidate standards of care in non-resectable liver cancer to improve outcomes.
Celsion is focused on the development and marketing of cancer treatment medication, and has research, license, or commercialization agreements with such institutions as the National Institutes of Health, Duke University Medical Center, and University of Hong Kong. Celsion's medicine technologies are being developed for applications such as tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology.
Poon is involved with Celsion as Lead Asia Pacific Principal Investigator for Celsion's Phase III HEAT Study of ThermoDox in primary liver cancer. The presentation, titled "Combining Thermal Ablation with Thermosensitive Liposomes," detailed the use of ThermoDox in conjunction with radiofrequency ablation (NYSEMKT:RFA). The HEAT study has received Fast Track designation, and as such is a Priority Trial with National Institutes of Health.
Said Poon, who was also lead investigator for the Phase I dose-determining study of ThermoDox in liver cancer, stated, "Liposomal encapsulation can optimize and enhance the delivery of effective cytotoxic agents with better drug cell internalization compared with free drug. With the growing incidence of primary liver cancer worldwide, physicians are in need of a treatment option that can safely and effectively reduce the rate of recurrence. The concept of heat-activated delivery of a cytotoxic drug using thermosensitive liposomes in combination with thermal ablation for liver cancer is capturing wide attention among interventional oncologists, and physicians involved in the treatment of liver cancer."
Michael H. Tardugno, Celsion's president and CEO added, "There is an urgent need for greater medical education and consensus in how we treat the growing, global epidemic of liver cancer. Professor Poon's presentation highlights the significance that ThermoDox may have in moving this effort forward. Celsion is eagerly awaiting the results from our pivotal Phase III HEAT Study, which we expect after 380 events of progression occur, projected for the fourth quarter of 2012. We look forward to announcing results following an independent review and confirmation by the study's data monitoring committee. With a successful outcome to the HEAT Study, ThermoDox provides the promise of a new and effective standard of care for intermediate-stage primary liver cancer."
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net